Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03882697 Recruiting - Prostate Cancer Clinical Trials

Ability of Cardio Q for Prediction of Hypotension

Start date: January 1, 2019
Study type: Observational

Evaluation the ability of each indicator of Cardio Q in predicting hypotension after position changes in robot-assisted laparoscopic radical prostatectomy

NCT ID: NCT03880851 Recruiting - Prostate Cancer Clinical Trials

MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)

Start date: January 23, 2019
Phase: N/A
Study type: Interventional

Single-centre single-armed, non-randomized interventional phase II-study of hypofractionated image-guided radiotherapy "IGRT" with weekly magnetic resonance imagings "MRI" for personalized adaptation of the treatment plan depending on individual MR-anatomy of prostate/organ at risks "OAR" during course of IGRT.

NCT ID: NCT03879486 Recruiting - Prostate Cancer Clinical Trials

Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate Biopsy

Start date: May 31, 2017
Phase: N/A
Study type: Interventional

The main purpose of this study is to compare the infectious outcomes of intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy. The secondary objective is to evaluate predictive factors of infectious complications after prostate biopsy. Data will be prospectively collected from patients who will undergo prostate biopsy in a single high volume urology center. The patients will be randomized to two different groups: group A - rectal cleansing and disinfection of the needle tip vs group B - controls.

NCT ID: NCT03876912 Recruiting - Prostate Cancer Clinical Trials

The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA PET/CT at baseline, 2-3 weeks after the initiation of GnRH-antagonist and at the time of castration resistant prostate cancer (CRPC). The aim of the study is to classify metastatic lesions into those with PSMA-flare and those without and determine their potential to progress during the follow-up until CRPC.

NCT ID: NCT03862170 Recruiting - Prostate Cancer Clinical Trials

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

Start date: February 10, 2015
Phase: Phase 3
Study type: Interventional

Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.

NCT ID: NCT03857477 Recruiting - Prostate Cancer Clinical Trials

The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.

Start date: March 14, 2019
Study type: Observational

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. A pilot of 300 men were recruited aiming to inform the feasibility and accessibility of the study approach. The full study is an extension of the pilot study aiming to recruit a total of 5000 men.

NCT ID: NCT03851926 Recruiting - Prostate Cancer Clinical Trials

Hypofraccionated Radiotherapy for Prostate Cancer

Start date: October 5, 2016
Study type: Observational

Radiotherapy is a standard definitive treatment for men with localized prostate cancer. Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days with lower doses to surrounding healthy tissues, trying to reduce side effects. This study is being proposed to evaluate the use of moderate hypofractionated volumètric radiotherapy in localized prostate cancer patients and assessing treatment -related later adverse events using the CTCAE 4.0

NCT ID: NCT03851211 Recruiting - Prostate Cancer Clinical Trials

Prolaris Enhanced Risk Stratification - an ecONomic and clinicAL Evaluation

Start date: February 21, 2019
Study type: Observational

One in 8 men will be diagnosed with prostate cancer during their lifetime. The majority of men diagnosed with prostate cancer have early stage disease, which can be managed in a variety of ways, ranging from monitoring to international treatment. However is it not always clear which treatment option is best. All men with newly diagnosed localised prostate cancer are assigned a disease risk category (low/intermediate/high risk). This is based on clinical findings and prostate biopsy results, but these factors are limited in their ability to distinguish between aggressive and indolent prostate cancers. The current risk grouping can make it difficult to plan appropriate treatment tailored and personalised to the individual patient. There is evidence reporting overtreatment of localised prostate cancer in the UK. However, many patients with aggressive disease are wrongly assigned a low risk categorisation and are recommended surveillance when better suited to more interventional treatment. Myriad Genetics have developed a test, called Prolaris which measures how fast cells in a prostate cancer are dividing to assess its aggressiveness. The Prolaris test is performed on routine prostate biopsy tissue, so patients are not subjected to any additional invasive investigations. In this study, led by Leeds Teaching Hospitals NHS Trust, the aim is find out if the Prolaris® test score helps patients with newly diagnosed prostate cancer and their clinical team make better informed treatment choices that are tailored to the individual patient. The aim to achieve a Prolaris risk score for 100 patients and determine the impact it has on treatment decision making. The research team will look at how the test fits into routine clinical practice, investigate the clinician and patient views and understanding on the test report and assess the quality of life of patients in the different risk and treatment groups.

NCT ID: NCT03838432 Recruiting - Prostate Cancer Clinical Trials

The Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Ablation Therapy

Start date: May 2, 2018
Phase: N/A
Study type: Interventional

This trial is studying the effects and safety in treating patients from five different centers with local prostate cancer, employing Composite Steep-pulse(High-frequency irreversible electroporation) Treatment Apparatus. This device could cause cell irreversible electroporation, which leading necrosis of tumor cells. It also has the ability to prevent nerve,vessel, urethral and capsule unnecessary injury beside the ablation area. Composite Steep-pulse Treatment Apparatus will be used in patients who pass inclusion/exclusion criteria. Safety, quality of life, and histopathological analysis of prostate speciem will be evaluated in each study patients.

NCT ID: NCT03824808 Recruiting - Prostate Cancer Clinical Trials

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Start date: February 11, 2019
Phase: Phase 4
Study type: Interventional

Controlling pain is fundamental during and after surgical procedures. This study examines pain associated with robotic assisted surgery on prostate cancer or a kidney mass. In recent years, the risk of opioids in the postoperative period has gained interest due to the growing epidemic of addiction, dependence, and overdose. In this study, the investigators expect a continuous infusion of intravenous lidocaine during the perioperative period to result in less pain and less opioid use.